YD Bio Limited
YDES evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for YDES—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · YDES
YD Bio Limited is a publicly traded biotechnology company focused on regulated diagnostics, life science clinical services, and healthcare product commercialization, with operations including DNA methylation-based oncology testing and clinical trial supply chain services.
Key risk: Limited cash and recurring losses
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Dec 31, 2025.
YD Bio Limited is a publicly traded biotechnology company focused on regulated diagnostics, life science clinical services, and healthcare product commercialization, with operations including DNA methylation-based oncology testing and clinical trial supply chain services.
- Cash & equivalents of $6.0M as of 2025-12-31 [sec].
- Total revenue of $0.6M and net loss of -$8.3M for the year ended 2025-12-31 [sec].
- Operates a CLIA- and CAP-certified laboratory platform across 44 U.S. states and Washington, D.C. and Guam through its affiliate EG BioMed [sec · filed 2026-04-30].
- Has announced a non-binding MOU to merge with EG BioMed and a binding LoI to acquire another entity, both in early 2026, to expand into AI-driven cancer diagnostics and drug discovery [sec · filed 2026-04-30].
- Plans to pursue IND submissions and clinical initiations beginning in 2026, subject to preclinical work, CMC readiness, and regulatory feedback [sec · filed 2026-04-30].
What works
- Operates an online platform for CLIA- and CAP-certified laboratory services across 44 U.S. states and Washington, D.C. and Guam, providing a scalable commercial infrastructure [sec · filed 2026-04-30].
- Has multi-decade, exclusive licensing agreements and an owned patent portfolio, which the company describes as providing a significant competitive advantage [sec · filed 2026-04-30].
- Targets large, underserved markets with projected multi-billion-dollar global market sizes over the next decade [sec · filed 2026-04-30].
What to weigh
- Has a limited cash position of $6.0M as of 2025-12-31 and a history of net losses, with a net loss of -$8.3M for the year ended 2025-12-31 [sec].
- The company's strategic acquisitions and partnerships are subject to various risks, including the ability to close transactions and realize anticipated benefits [sec · filed 2026-04-30].
- Relies on third-party manufacturers and license agreements, which are critical to its business and subject to risks of capacity and dependency [sec · filed 2026-04-30].
- Forward-looking statements note that the company's ability to execute its strategy depends on capital availability, regulatory approvals, and market conditions, with no assurance of achieving expected results [sec · filed 2026-04-30].
From the filings
Quoted directly from source documents.
Operates CLIA- and CAP-certified lab services across 44 U.S. states
“operates an online platform for CLIA- and CAP-certified laboratory services across 44 U.S. states and Washington, D.C. and Guam”
SEC filings · April 30, 2026
Announced MOU to merge with EG BioMed
“a non-binding Memorandum of Understanding (MOU) announced on January 6, 2026, to merge with EG BioMed”
SEC filings · April 30, 2026
Risks & what to watch (4)›
Key risks
- Limited cash and recurring losses — Cash of $6.0M and net loss of -$8.3M as of 2025-12-31, indicating potential need for additional capital [sec].
- Strategic acquisition execution risk — The MOU and LoI transactions may not close or achieve anticipated synergies, subject to conditions and regulatory approvals [sec · filed 2026-04-30].
- Dependence on third-party partners — Relies on license agreements and third-party manufacturers, which are critical and subject to risks of capacity and dependency [sec · filed 2026-04-30].
- Regulatory and market uncertainties — Clinical programs and IND submissions depend on preclinical results, CMC readiness, and regulatory feedback; timelines are uncertain [sec · filed 2026-04-30].
What to watch
- Closure of the MOU to merge with EG BioMed and the binding LoI, which could expand the company's AI-driven diagnostics and drug discovery capabilities [sec · filed 2026-04-30].
- Progress of IND submissions and clinical initiations planned for 2026, subject to preclinical and regulatory milestones [sec · filed 2026-04-30].
- Expansion of clinical services through the partnership with YC Biotech, including support for IND, NDA, and BLA activities [sec · filed 2026-04-30].
- Asia market expansion plans, which the company expects to establish as its first international growth region [sec · filed 2026-04-30].
Sources: SEC filings · Generated August 29, 2026 · How we verify sources →
Run YD Bio Limited through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available YD Bio Limited facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
3.2 months
OCF -$7M · Net income -$8M
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
6
Total value held
$889K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 60,236 | $464K |
| cypress capital management llc (wy) | 30,690 | $236K |
| citadel advisors llc | 19,450 | $150K |
| wolverine asset management llc | 4,886 | $38K |
| morgan stanley | 223 | $2K |
| fmr llc | 1 | $8 |
Short Interest
as of May 22, 2026- % of float
- 0.1%
- Days to cover
- 0.9
- Shares short
- 21,864
- Daily short volume (Aug 13, 2026)
- 51.9%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
YDES short interestFrequently asked questions
What is the AI investment thesis for YD Bio Limited?
YD Bio Limited is a publicly traded biotechnology company focused on regulated diagnostics, life science clinical services, and healthcare product commercialization, with operations including DNA methylation-based oncology testing and clinical trial supply chain services.
Who is the CEO of YD Bio Limited?
Dr. Ethan Shen Ph.D. is the chief executive officer of YD Bio Limited (YDES).
Where is YD Bio Limited headquartered?
YD Bio Limited (YDES) is headquartered in Taipei, Taiwan.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.